Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Stephanie Saw Pei Li
Published by HT Digital Content Services with permission from Health Daily Digest....